A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"

NCT01903993 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

287

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Docetaxel
DRUG: Atezolizumab

Sponsor

Hoffmann-La Roche